Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations

European Journal of Cancer Prevention

Volumn 21, Issue 3, 2012, Pages 247-253

  Rozen, Paul ^a,b   Liphshitz, Irena ^c   Barchana, Micha ^a,c  

^a UNIVERSITY OF HAIFA   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MINISTRY OF HEALTH   (Israel)

Author keywords

adenoma; age; colonoscopy; colorectal cancer; occult blood screening; sex

Indexed keywords

ADENOMATOUS POLYP; ADULT; AGED; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GOLD STANDARD; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PRIORITY JOURNAL; REVIEW;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 84859421399     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834c9cc6     Document Type: Review

References (39)

1. Brenner H, Haug U, Hundt S (2010). Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 105:2457-2464.
2. Bressler B, Paszat LF, Vinden C, Li C, He J, Rabeneck L (2004). Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 127:452-456. (Pubitemid 39091893)
3. Chen LS, Yen AM, Chiu SY, Liao CS, Chen HH (2011). Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 12:551-558.
4. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, Grazzini G, et al. (2007). Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 96: 218-221. (Pubitemid 46160624)
5. Crotta S, Castiglione G, Grazzini G, Valle F, Mosconi S, Rosset R (2004). Feasibility study of colorectal cancer screening by immunochemical faecal occult blood testing: results in a northern Italian community. Eur J Gastroenterol Hepatol 16:33-37. (Pubitemid 39043700)
6. Diamond SJ, Enestvedt BK, Jiang Z, Holub JL, Gupta M, Lieberman DA, Eisen GM (2011). Adenoma detection rate increases with each decade of life after 50 years of age. Gastrointest Endosc 74:135-140.
7. Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. (2011). Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 128:3-11.
8. Fenocchi E, Martinez L, Tolve J, Montano D, Rondán M, Parra-Blanco A, et al. (2006). Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev 15:384-390. (Pubitemid 44252909)
9. Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Ostbye T, et al. (2011). Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol 106:1125-1134.
10. Gimeno-García AZ, Quintero E, Nicolás-Pérez D, Hernández-Guerra M, Parra-Blanco A, Jiménez-Sosa A (2009). Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. Eur J Gastroenterol Hepatol 21:1062-1067.
11. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, et al. (2009). Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 100:259-265.
12. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al. (2009). Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 125:1127-1133.
13. Hazazi R, Rozen P, Leshno M, Levi Z, Samuel Z, Waked A, et al. (2010). Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy? Aliment Pharmacol Ther 31:523-533.
14. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, et al. (2009). Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 100:1103-1110.
15. Hosokawa O, Shirasaki S, Kaizaki Y, Hayashi H, Douden K, Hattori M (2003). Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer. Endoscopy 35:506-510. (Pubitemid 36705642)
16. Israel National Cancer Registry (2010). www.health.gov.il/icr [Accessed 2010].
17. Lane JM, Chow E, Young GP, Good N, Smith A, Bull J, et al. (2010). Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 139:1918-1926.
18. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AVN, Bouvier VM, et al. (2005). Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 115:493-496. (Pubitemid 40663756)
19. Leiberman DA, Holub J, Eisen G, Kraemer D, Morris CD (2005). Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 62:875-883. (Pubitemid 41654422)
20. Levi Z, Rozen P, Hazazi R, Vilkin A,Waked A, Maoz E, et al. (2007). A quantitative immunochemical fecal occult blood screening test for colorectal neoplasia. Ann Intern Med 146:244-255. (Pubitemid 351650610)
21. Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. (2011). A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 128:2415-2424.
22. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y (2005). A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129:422-428. (Pubitemid 41096630)
23. Nakama H, Zhang B, Fukazawa K, Zhang X (2001). Comparisons of cancer detection rate and costs of one cancer detected among different age-cohorts in immunochemical occult blood screening. J Cancer Res Clin Oncol 127:439-443. (Pubitemid 32524361)
24. Nishida H, Urano S (2011). Effectiveness of repeated screening using the fecal occult blood test and its impact on reducing false-negative cancer cases. Eur J Cancer Prev 20:184-189.
25. Oono Y, Iriguchi Y, Doi Y, Tomino Y, Kishi D, Oda J, et al. (2010). A retrospective study of immunochemical fecal occult blood testing for colorectal cancer detection. Clin Chim Acta 411:802-805.
26. Pabby A, Schoen RE,Weissfeld JL, Burt R, Kikendall JW, Lance P, et al. (2005). Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 61:385-391. (Pubitemid 40349030)
27. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, et al. (2010). Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 105:2017-2025.
28. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, et al. (1997). Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 112:24-28. (Pubitemid 27008981)
29. Rozen P, Levi Z, Hazazi R,Waked A, Vilkin A, Maoz E, et al. (2009a). Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 29:906-917.
30. Rozen P, Levi Z, Hazazi R,Waked A, Vilkin A, Maoz E, et al. (2009b). Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 29:450-457.
31. Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, et al. (2010). Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 116:2115-2125.
32. Rozen P, Liphshitz I, Barchana M (2011). The changing epidemiology of colorectal cancer and its relevance for adapting screening guidelines and methods. Eur J Cancer Prev 20:46-53.
33. Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, et al. (2005). Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 352:2061-2068. (Pubitemid 40664307)
34. SEER Program (1999). Self-Instructional Manual for Cancer Registrars. 3rd edition USA: National Institutes of Health, National Cancer Institute.
35. Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I (2011). Costeffectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum 54:876-886.
36. Terhaarsive Droste JS, Oort FA, van der Hulst RWM, van Heukelem HA, Loffeld RJ, van Turenhout ST, et al. (2011). Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev 20: 272-280.
37. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, et al. (2009). Cutoff value determines the performance of a semiquantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 101:1274-1281.
38. Van Rossum LG, van Rijn AF, Verbeek ALM, van Oijen MGH, Laheij RJF, Fockens P, et al. (2011). Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 28:1908-1917.
39. Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. (2005). Performance characteristics and evaluation of an automated developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 100:2519-2526.